JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB205340

Anti-beta Amyloid 抗体 [mOC23] - Conformation-Specific

Anti-beta Amyloid antibody [mOC23] - Conformation-Specific

  • BOND RX™ Validated
  • 20ul selling size
  • RabMAb
  • Recombinant
  • 詳細を見る

4

(1 Review)

|

(3 Publications)

Rabbit Recombinant Monoclonal Amyloid-beta precursor protein antibody. Suitable for IHC-P, Dot and reacts with Human, Synthetic peptide samples. Cited in 3 publications.

別名を表示する

A4, AD1, APP, Amyloid-beta precursor protein, ABPP, APPI, Alzheimer disease amyloid A4 protein homolog, Alzheimer disease amyloid protein, Amyloid precursor protein, Amyloid-beta (A4) precursor protein, Amyloid-beta A4 protein, Cerebral vascular amyloid peptide, PreA4, Protease nexin-II, CVAP, PN-II

3 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-beta Amyloid antibody [mOC23] - Conformation-Specific (AB205340)
  • IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-beta Amyloid antibody [mOC23] - Conformation-Specific (AB205340)

IHC image of beta Amyloid staining in Human Brain Alzheimer formalin fixed paraffin embedded tissue section*, performed on a Leica Bond™ system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab205340, 0.1μg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

*Tissue obtained from the Human Research Tissue Bank, supported by the NIHR Cambridge Biomedical Research Centre

Dot Blot - Anti-beta Amyloid antibody [mOC23] - Conformation-Specific (AB205340)
  • Dot

Supplier Data

Dot Blot - Anti-beta Amyloid antibody [mOC23] - Conformation-Specific (AB205340)

Dot blot analysis of beta Amyloid labeled with ab205340 at 1/6000 dilution.

Lane 1 : beta Amyloid (Aβ) 1-40;

Lane 2 : beta Amyloid (Aβ) 1-42.

Goat Anti-Rabbit IgG (H+L) Peroxidase conjugated (ab97051) at 1/30000 was used as secondary antibody.

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : 30 seconds.

Note : Antibody reactivity was assessed using a dot blot which is a non-quantitative method that maintains the native conformation of beta Amyloid. beta Amyloid 1-40 and 1-42 peptides underwent the following aggregation conditions before being spotted onto a nitrocellulose membrane and detected using ab205340 :

Monomers : 0.3 mg of beta Amyloid peptide was dissolved in 30 μl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 μl of 1% SDS and boiled for five minutes.

Oligomers : 0.3 mg of beta Amyloid peptide was dissolved in 30 μl 100 mM NaOH and incubated at room temperature for 10 minutes. It was then diluted with 970 μl of 10 mM phosphate buffer pH 7.4 containing 0.02% sodium azide and incubated at room temperature for four days.

Fibrils : 0.3 mg of beta Amyloid peptide was dissolved in 1 ml 50% hexafluoroisopropanol (HFIP) with 0.02% sodium azide. It was then stirred constantly for nine days; the first seven with a cap on and the final two with the cap removed to allow evaporation of the HFIP. Fibrils were then sedimented at 20000 rpm in a microcentrifuge for 20 minutes and resuspended in 1 ml of PBS + 0.02% sodium azide.

Dot Blot - Anti-beta Amyloid antibody [mOC23] - Conformation-Specific (AB205340)
  • Dot

Unknown

Dot Blot - Anti-beta Amyloid antibody [mOC23] - Conformation-Specific (AB205340)

Negative control (secondary ab only) Dot blot analysis of beta Amyloid.

Lane 1 : beta Amyloid (Aβ) 1-40;

Lane 2 : beta Amyloid (Aβ) 1-42.

Goat Anti-Rabbit IgG (H+L) Peroxidase conjugated (ab97051) at 1/30000 was used as secondary antibody.

Blocking/Dilution buffer : 5% NFDM/TBST.

Exposure time : 30 seconds.

関連する標識済み抗体及び組成の異なる製品 (1)

  • Carrier free

    Anti-beta Amyloid antibody [mOC23] - BSA and Azide free

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

mOC23

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

IHC-P, Dot

applications

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "Dot" : {"fullname" : "Dot Blot", "shortname":"Dot"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "0.1-0.5 µg/mL", "IHCP-species-notes": "<p></p>", "Dot-species-checked": "guaranteed", "Dot-species-dilution-info": "", "Dot-species-notes": "" }, "Synthetic peptide": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "Dot-species-checked": "testedAndGuaranteed", "Dot-species-dilution-info": "1/6000", "Dot-species-notes": "<p></p>" } } }

製品の詳細

This antibody was developed as part of a collaboration between Abcam and Professor Charles Glabe, UC Irvine.

ab205340 (mOC23) recognizes an aggregation-dependent epitope of Aß that maps to a linear segment of Aß (residues 2-6, AEFRH) (Hatami et al 2014, PMID: 25281743). mOC23 stains a subset of plaques, but weakly stains the central core of cored plaques. mOC23 also stains misfolded or aggregated intraneuronal amyloid deposits (Hatami et al 2014, PMID: 25281743). Immunoreactivity on western blots is decreased by boiling the membrane.

For further information on the immunogen, please refer to Hatami et al 2014, PMID: 25281743 and Kayed et al. 2007, PMID: 17897471.

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

Beta amyloid also known as amyloid beta peptide is a small protein fragment composed of 36-43 amino acids. It typically has a mass of approximately 4 kDa. This peptide primarily emerges from the amyloid precursor protein (APP) through enzymatic actions by beta-secretase and gamma-secretase. Beta amyloid is commonly expressed in the brain particularly within the neuronal tissue. It is known for aggregating into insoluble fibrils leading to the formation of beta amyloid plaques. Researchers often study beta amyloid using tools like amyloid beta IHC and with specific antibodies like moab 2 and 2e9 which help in detecting its presence and distribution.
Biological function summary

In the context of neuronal function beta amyloid is significant yet contentious. It is believed to play a role in synaptic transmission and may partake in homeostatic regulation. However the true physiological role still remains not well defined. Beta amyloid often self-assembles into oligomers and further into beta amyloid plaques which are part of a larger complex that includes various cellular and molecular components. The plaques contribute to neural pathway disruptions and may interfere with synaptic connections.

Pathways

Beta amyloid integrates into important cellular processes such as the amyloidogenic and non-amyloidogenic pathways. The amyloidogenic pathway involves the sequential cleavage of APP by beta and gamma secretases leading to beta amyloid release which can aggregate. In contrast the non-amyloidogenic pathway mediated by alpha-secretase precludes beta amyloid formation. Proteins such as presenilin-1 and nicastrin are closely tied to beta amyloid formation due to their roles in the gamma-secretase complex.

Beta amyloid is primarily associated with Alzheimer's disease where its accumulations form characteristic amyloid plaques observed in patients' brains. These plaques are implicated in neuronal damage and cognitive decline. Beyond Alzheimer's beta amyloid may also connect to cerebral amyloid angiopathy a condition marked by amyloid deposits in the blood vessels of the brain leading to increased risk of hemorrhagic stroke. Recent studies suggest other proteins such as tau link closely with beta amyloid pathology in Alzheimer's promoting neurofibrillary tangles and synaptic degeneration.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis (PubMed : 25122912). Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1 (By similarity). By acting as a kinesin I membrane receptor, plays a role in axonal anterograde transport of cargo towards synapses in axons (PubMed : 17062754, PubMed : 23011729). Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.. Amyloid-beta peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Amyloid-beta peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts.. Amyloid-beta protein 42. More effective reductant than amyloid-beta protein 40. May activate mononuclear phagocytes in the brain and elicit inflammatory responses.. Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain.. The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.
See full target information APP

文献 (3)

Recent publications for all applications. Explore the full list and refine your search

Acta neuropathologica communications 10:182 PubMed36529803

2022

Cognitively impaired aged Octodon degus recapitulate major neuropathological features of sporadic Alzheimer's disease.

Applications

Unspecified application

Species

Unspecified reactive species

Zhiqun Tan,B Maximiliano Garduño,Pedro Fernández Aburto,Lujia Chen,Nicole Ha,Patricia Cogram,Todd C Holmes,Xiangmin Xu

The Journal of biological chemistry 296:100168 PubMed33298522

2020

An "epitomic" analysis of the specificity of conformation-dependent, anti-Aß amyloid monoclonal antibodies.

Applications

Unspecified application

Species

Unspecified reactive species

Jorge Mauricio Reyes-Ruiz,Rie Nakajima,Ibtisam Baghallab,Luki Goldschmidt,Justyna Sosna,Phuong Nguyen Mai Ho,Taha Kumosani,Philip L Felgner,Charles Glabe

The Journal of biological chemistry 289:32131-43 PubMed25281743

2014

Monoclonal antibodies against Aβ42 fibrils distinguish multiple aggregation state polymorphisms in vitro and in Alzheimer disease brain.

Applications

Unspecified application

Species

Unspecified reactive species

Asa Hatami,Ricardo Albay,Sanaz Monjazeb,Saskia Milton,Charles Glabe
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com